Literature DB >> 3459562

The nature of blast cells in myelodysplastic syndromes evolving to acute leukaemia.

J F San Miguel, M González, M C Cañizo, J P Anta, J Hernández, F Ortega, L Borrasca.   

Abstract

The blast cells from nine patients with an overt acute leukaemia following a previous myelodysplastic syndrome (MDS) are analyzed with a panel of monoclonal antibodies as well as by morphological and cytochemical criteria. By integrating the results obtained with these three approaches the leukaemia in 6 patients was assessed as myeloid-granulocytic and/or monocytic-, in two as mixed- megakaryoblastic/myeloid- and in one as lymphoid. A good correlation between morphology, cytochemistry and immunological markers was observed in 7 out of the 9 cases. In three cases a noteworthy percentage of J5+ cells was detected. The exceptional finding of lymphoid as well as megakaryocytic and myeloid transformations suggests that the target cell for these leukaemias could be a pluripotent stem cell.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459562     DOI: 10.1007/BF00320782

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  27 in total

1.  Refractory sideroblastic anaemia and erythraemic myelosis: possible relationship and cytochemical observations.

Authors:  F G HAYHOE; D QUAGLINO
Journal:  Br J Haematol       Date:  1960-10       Impact factor: 6.998

2.  Monoclonal antibodies that bind to the human erythrocyte-membrane glycoproteins glycophorin A and Band 3 [proceedings].

Authors:  P A Edwards
Journal:  Biochem Soc Trans       Date:  1980-06       Impact factor: 5.407

3.  A differentiation antigen expressed selectively by a proportion of human blood cells: detection with a monoclonal antibody.

Authors:  D A Brooks; J Bradley; H Zola
Journal:  Pathology       Date:  1982-01       Impact factor: 5.306

4.  Distribution of Ia-like molecules on the surface of normal and leukemic human cells.

Authors:  S F Schlossman; L Chess; R E Humphreys; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

5.  Monoclonal antibodies against antigens of the human platelet surface: preparation and properties.

Authors:  H Zola; P J McNamara; I G Beckman; D A Brooks; P J Macardle; J Bradley; K Goodall; J Skinner; R Collins; M C Berndt
Journal:  Pathology       Date:  1984-01       Impact factor: 5.306

6.  The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.

Authors:  G Tricot; M A Boogaerts; C De Wolf-Peeters; H Van den Berghe; R L Verwilghen
Journal:  Br J Haematol       Date:  1985-04       Impact factor: 6.998

7.  Immune phenotype heterogeneity in AML.

Authors:  A Ost; B Christensson; R Andreasen; R Hast; B Lagerlöf; P Reizenstein; I S Trowbridge; P Biberfeld
Journal:  Scand J Haematol       Date:  1985-04

8.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

9.  Antigens on human monocytes identified by monoclonal antibodies.

Authors:  R F Todd; L M Nadler; S F Schlossman
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

10.  Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients.

Authors:  W Vainchenker; J F Deschamps; J M Bastin; J Guichard; M Titeux; J Breton-Gorius; A J McMichael
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

View more
  1 in total

Review 1.  Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature.

Authors:  Norihide Sato; Tomonori Nakazato; Masahiro Kizaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.